Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2017. The document serves as a transaction notification regarding a specific securities transaction involving the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a single transaction event:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of ADSs via dividend reinvestment under the US Deferred Performance Share Plan.
- Transaction Date: October 12, 2017.
- Exchange: New York Stock Exchange (XNYS).
- Price: $41.02 per ADS.
- Total Volume: 383.749 ADSs (comprising 377.925 and 5.824 units).
Material Changes
The filing does not provide comparative financial data or material changes in the company's operational performance versus prior periods. The only change reported is the increase in ADS holdings by a Person Closely Associated (PCA) with the company due to the dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a mandatory disclosure of a specific insider-related transaction.
Key Facts for Investor Verification
- Verify the identity of the reporting individual: Mr. D E Troy, SVP & General Counsel.
- Confirm the transaction was an acquisition of ADSs through dividend reinvestment, not an open market purchase.
- Note the transaction price of $41.02 on October 12, 2017, for valuation context.
- Understand that this filing does not reflect the company's broader financial health or quarterly results.